Rodman & Renshaw Global Healthcare Conference 2008 takes place May
19-20, 2008 at the Le Meridien Beach Plaza Hotel, in Monte Carlo
Monaco. In-depth information about the event is available at http://www.rodmanandrenshaw.com/conferences?id=18&link=confinfo.
Business Wire is the official news wire for the Rodman & Renshaw Global
Healthcare Conference. Listed below are profiles from the conference
presenters. Breaking news releases and photos are available at http://www.tradeshownews.com
Business Wire´s trade show, conference, and event news resource.
= = = = = = = = = = =
Company:
Access Pharmaceuticals, Inc.
- - - - - -
Ticker Symbol & Exchange:
ACCP.OB
- - - - - -
Investor Relations Contact:
Stephen B. Thompson
- - - - - -
Investor Relations Contact Phone:
214-905-5100
- - - - - -
Web:
www.accesspharma.com
- - - - - -
Date of Presentation:
Monday, May 19, 2008
- - - - - -
- - - - - -
Access Pharmaceuticals, Inc. (ACCP.OB) is an emerging pharmaceutical
company focused on the development and commercialization of
proprietary products for the treatment and supportive care of cancer
patients. Access has one approved product, MuGard? for the management of oral mucositis. The company´s
lead oncology product is ProLindacâ„¢
a
polymer-linked platinum cancer drug, which is in Phase 2 clinical
testing in recurrent ovarian cancer patients. Angiolix®
an antiangiogenic humanized monoclonal antibody, and Prodrax®
a hypoxia-activated prodrug, are the company´s
lead preclinical oncology products. Access is also developing oral
insulin and oral hGH using its proprietary Cobalaminâ„¢ oral drug delivery technology.
- - - - - -
- - - - - -
Company:
Active Biotech AB
- - - - - -
Ticker Symbol & Exchange:
ACTI OMX Nordic
- - - - - -
Investor Relations Contact:
Göran Forsberg
- - - - - -
Investor Relations Contact Phone:
46 46 19 11 54
- - - - - -
Web:
www.activebiotech.com
- - - - - -
Date of Presentation:
20-May
- - - - - -
- - - - - -
Active Biotech AB (OMX Nordic: ACTI) is a biotechnology company
focusing on research and development of pharmaceuticals. Active
Biotech has a strong R&D portfolio with pipeline products focused on
autoimmune/inflammatory diseases and cancer. Most advanced projects
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis
as well as ANYARA for use in cancer targeted therapy, primarily
renal cancer. Further key projects in clinical development comprise
the three orally administered compounds TASQ for prostate cancer
57-57 for SLE and RhuDex® for RA.
- - - - - -
- - - - - -
Company:
Addex Pharma SA
- - - - - -
Ticker Symbol & Exchange:
ADXN
- - - - - -
Investor Relations Contact:
Chris Maggos
- - - - - -
Investor Relations Contact Phone:
41 22 884 15 11
- - - - - -
Web:
www.addexpharma.com
- - - - - -
Date of Presentation:
20/05/2008
- - - - - -
- - - - - -
Addex Pharmaceuticals Ltd discovers and develops allosteric
modulators, an emerging class of small molecule therapeutic agents.
Allosteric modulation may offer more sophisticated ways to normalize
biological signaling compared to classical orthosteric agonist or
antagonist drugs.
- - - - - -
- - - - - -
Lead product, ADX10059, a negative allosteric modulator (NAM) of
metabotropic glutamate receptor 5 (mGluR5), showed clinically and
statistically significant efficacy in separate Phase IIa clinical
trials in gastroesophageal reflux disease (GERD) and migraine. The
company has 12 early stage products.
- - - - - -
- - - - - -
The Addex allosteric modulation discovery and development platform
has been additionally validated through product collaborations with
Merck & Co., Inc. and Johnson & Johnson.
- - - - - -
- - - - - -
Company:
Biosante Pharmaceuticals, Inc.
- - - - - -
Ticker Symbol & Exchange:
BPAX/NASDAQ
- - - - - -
Investor Relations Contact:
Phillip Donenberg
- - - - - -
Investor Relations Contact Phone:
847-478-0500 ext 100
- - - - - -
Web:
www.biosantepharma.com
- - - - - -
Date of Presentation:
19-May-08
- - - - - -
- - - - - -
BioSante is a specialty pharmaceutical company focused on developing
products for female sexual health, menopause, contraception and male
hypogonadism. BioSante´s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by
BioSante under a U.S. Food and Drug Administration (FDA) SPA
(Special Protocol Assessment) for the treatment of female sexual
dysfunction (FSD), and Elestrinâ„¢ (estradiol gel) developed through FDA approval by BioSante
indicated for the treatment of moderate-to-severe vasomotor symptoms
associated with menopause, currently marketed in the U.S. Also in
development are Bio-T-Gelâ„¢
a
testosterone gel for male hypogonadism, and an oral contraceptive in
Phase II clinical development using BioSante patented technology.
- - - - - -
- - - - - -
Company:
Cyclacel Pharmaceuticals, Inc.
- - - - - -
Ticker Symbol & Exchange:
CYCC
- - - - - -
Investor Relations Contact:
Corey Sohmer
- - - - - -
Investor Relations Contact Phone:
1 908 517 7330
- - - - - -
Web:
www.cyclacel.com
- - - - - -
Date of Presentation:
May 20th
- - - - - -
- - - - - -
Cyclacel is a diversified biopharmaceutical business dedicated to
the discovery, development and commercialization of novel, targeted
drugs to treat cancer. Cyclacel´s
strategy is focused on leading edge therapeutic management of cancer
patients based on a portfolio of three medicines marketed by its
ALIGN subsidiary and a deep development pipeline. Three
orally-available drugs are in clinical development: sapacitabine (in
two randomized Phase 2 studies for the treatment of elderly acute
myeloid leukemia and cutaneous T-cell lymphoma); seliciclib (in two
randomized Phase 2 studies for the treatment of lung and
nasopharyngeal cancers) and CYC116 (in Phase 1 in patients with
solid tumors).
- - - - - -
- - - - - -
Company:
Cytori Therapeutics
- - - - - -
Ticker Symbol & Exchange:
CYTX
- - - - - -
Investor Relations Contact:
Tom Baker
- - - - - -
Investor Relations Contact Phone:
858.458.0900
- - - - - -
Web:
www.cytoritx.com
- - - - - -
Date of Presentation:
5.19.08
- - - - - -
- - - - - -
Cytori Therapeutics´ (NASDAQ:CYTX) goal is to be the global leader
in regenerative medicine. The company is dedicated to providing
patients with new options for reconstructive surgery, developing
treatments for cardiovascular disease, and banking patients´ adult
stem and regenerative cells. The Celution® 800 System is being introduced in Europe into the reconstructive
surgery market while the Celutionâ„¢ 900
System will be launched in Asia-Pacific for cryopreserving a
patient´s own stem and regenerative cells. Clinical trials are
ongoing in cardiovascular disease and planned for spinal disc
degeneration, gastrointestinal disorders, and other unmet medical
needs. www.cytoritx.com
- - - - - -
- - - - - -
Company:
DOV Pharmaceutical, Inc.
- - - - - -
Ticker Symbol & Exchange:
DOVP.OB
- - - - - -
Investor Relations Contact:
Barbara Duncan
- - - - - -
Investor Relations Contact Phone:
732-907-3604
- - - - - -
Web:
www.dovpharm.com
- - - - - -
Date of Presentation:
19-May-08
- - - - - -
- - - - - -
DOV is a biopharmaceutical company focused on the development of
novel product candidates for disorders of the central nervous
system, or CNS. We currently have drug development programs that
are at the preclinical, Phase I and Phase II clinical stages
including DOV 21, 947 (in a Phase II clinical trial for
depression), DOV 102,677 (which has completed a Phase I clinical
trial) and a preclinical discovery program in reuptake inhibitors
and GABA modulators.
- - - - - -
- - - - - -
Company:
Evotec AG
- - - - - -
Ticker Symbol & Exchange:
FSE:EVT, NASDAQ:EVTC
- - - - - -
Investor Relations Contact:
Anne Hennecke
- - - - - -
Investor Relations Contact Phone:
49-40-56081-286
- - - - - -
Web:
www.evotec.com
- - - - - -
Date of Presentation:
May 20, 2008, 11.00 am CET
- - - - - -
- - - - - -
Evotec is a leader in the discovery and development of novel small
molecule drugs. In proprietary projects, Evotec specializes in
finding new treatments for diseases of the CNS. Evotec has 3
programs in clinical development: EVT201, a partial positive
allosteric modulator of the GABA-A receptor complex for the
treatment of insomnia, EVT101, a subtype selective NMDA receptor
antagonist for the treatment of Alzheimer´s disease and/or pain, and
EVT302, a MAO-B inhibitor in development for smoking cessation.
Evotec´s proprietary preclinical research programs focus on the
purinergic receptors, P2X3 and P2X7, for the potential treatment of
pain and inflammatory diseases. In addition, Evotec has worldwide
collaboration and license agreements with Pfizer to research
develop and commercialize small molecule vanilloid receptor (VR1)
antagonists.
- - - - - -
- - - - - -
Company:
FIBREX MEDICAL Inc.
- - - - - -
Investor Relations Contact:
Rainer Henning, President & CE
- - - - - -
Investor Relations Contact Phone:
43-1-86634-9270
- - - - - -
Web:
www.fibrexmedical.com
- - - - - -
Date of Presentation:
20-May
- - - - - -
- - - - - -
FIBREX MEDICAL is a development stage biopharmaceutical company
with operations in Vienna/Austria. The company mission is to
develop and commercialize innovative therapeutics in the fields of
cardiovascular diseases and inflammation. FIBREX MEDICAL is
discovering and developing peptides and peptide analogs with
anti-inflammatory and endothelial protectant activity. Lead
compound FX06MRI is under clinical evaluation for the treatment of
reperfusion injury after myocardial infarction via a novel
mechanism of action.
- - - - - -
- - - - - -
Company:
Genetic Imunity
- - - - - -
Investor Relations Contact:
Dr. Julianna Lisziewicz ; Dr. Zsolt Lisziewicz
- - - - - -
Investor Relations Contact Phone:
36-302-116402
- - - - - -
Web:
www.geneticimmunity.com
- - - - - -
Date of Presentation:
May 19: from 09:20 to 09:40 AM
- - - - - -
- - - - - -
Genetic Immunity is a US/Hungarian clinical stage biopharmaceutical
company focused on the discovery, development and commercialization
of topically administered Nanomedicines for targeted immune
amplification. The Company´s Nanomedicine
platform focuses on significant unmet medical needs such as
infectious diseases, cancer and allergies. The DermaVir Patch
Genetic Immunity´s lead Nanomedicine candidate, is in Phase II
clinical development and could be the first Nanomedicine approved
for HIV/AIDS. Phase I/II trials to date of the DermaVir Patch have
confirmed safety and tolerability and the amplification of
HIV-specific T cell precursors (PHPC), which correlate with
decreased viral load (Caralota et al, J Immunol 2008).
- - - - - -
- - - - - -
Company:
GTC Biotherapeutics
- - - - - -
Ticker Symbol & Exchange:
GTCB NASDAQ
- - - - - -
Investor Relations Contact:
Thomas Newberry
- - - - - -
Investor Relations Contact Phone:
508-370-5374
- - - - - -
Web:
www.gtc-bio.com
- - - - - -
Date of Presentation:
20-May-08
- - - - - -
- - - - - -
GTC Biotherapeutics develops, produces, and commercializes
therapeutic proteins through transgenic animal technology. ATryn®
GTC´s recombinant form of human
antithrombin, is approved by the European Commission for use in
patients with hereditary antithrombin deficiency undergoing surgical
procedures. This was the first approval anywhere in the world of a
therapeutic protein produced from a transgenic animal. GTC´s
transgenic production platform is particularly well suited to
enabling cost effective development of proteins that are difficult
to express in traditional recombinant production systems as well as
those that are required in large volumes at a competitive cost.
Additional information is at http://www.gtc-bio.com.
- - - - - -
- - - - - -
Company:
Haemacure
- - - - - -
Ticker Symbol & Exchange:
HAE: TSX
- - - - - -
Investor Relations Contact:
Joseph Galli - 1.514.990.7074
- - - - - -
Investor Relations Contact Phone:
Diane Roch - 514.282.3350 x27
- - - - - -
Web:
www.haemacure.com
- - - - - -
Date of Presentation:
May 20 at 1:40p.m. - Zephir Room
- - - - - -
- - - - - -
Haemacure is a specialty biotherapeutics company developing
high-value human plasma-derived protein products for
commercialization. Haemacure´s research and development effort is
driven by its proprietary plasma protein extraction technology to
develop next-generation products, including surgical hemostats.
Haemacure´s lead product candidate, Hemaseel®HMN
is a fibrin sealant planned to enter pivotal Phase II/Phase III
clinical trials during the first quarter of 2009. Haemacure´s second
product candidate is thrombin, a component of its fibrin sealant
now in preclinical stage. Follow-on development will focus on
surgical hemostats, wound healing, adhesion prevention, regenerative
medecine, drug delivery and combination with biomaterials.
Additional information available on www.haemacure.com.
- - - - - -
- - - - - -
Company:
Helsinn Healthcare SA
- - - - - -
Investor Relations Contact:
Alessandro Bossi
- - - - - -
Investor Relations Contact Phone:
41 (0) 91 9852121 41 (0) 79 5084705
- - - - - -
Web:
www.helsinn.com
- - - - - -
Date of Presentation:
May 19, 2008 12:30pm (10:30am GMT)
- - - - - -
- - - - - -
Helsinn Healthcare SA announced today that Mr.Riccardo Braglia, CEO
will present an overview of the company, its products and corporate
goals at the Rodman & Renshaw Global Healthcare Conference, Monte
Carlo, Monaco on May 19th 2008 at 12:30pm (10:30am GMT). The
presentation will be webcast live and can be accessed by logging on
to the web site (www.wsw.com/webcast/rrshq13/helsinn). An archived
version is available for 90 days.
- - - - - -
- - - - - -
Helsinn (www.helsinn.com) is a privately owned Swiss-based
pharmaceutical group. Core business: pain, inflammation, oncology
and supportive care. Business strategy: in-license early stage new
chemical entities, complete their development up to market approvals
and out-license to its worldwide network of partners. The active
pharmaceutical ingredients and drug products are manufactured at
Helsinn´s cGMP facilities.
- - - - - -
- - - - - -
Company:
Hythiam, Inc.
- - - - - -
Ticker Symbol & Exchange:
HYTM: NASDAQ
- - - - - -
Investor Relations Contact:
Lisa Wilson
- - - - - -
Investor Relations Contact Phone:
In-Site Communications, Inc., 212-759-3929
- - - - - -
Web:
www.hythiam.com
- - - - - -
Date of Presentation:
Monday, May 19, 2008 at 5:15 pm
- - - - - -
- - - - - -
Hythiam, Inc. provides behavioral health management services to
health plans, employers, criminal justice, and government agencies
through a network of licensed and company managed healthcare
providers. Hythiam approaches the management of behavioral health
disorders with a focus on using the latest medical and health
technology aimed towards improved outcomes and out-patient
treatment. Hythiam offers disease management for substance
dependence built around its patented PROMETA Treatment Program for
alcoholism and dependence to stimulants. Hythiam also researches
develops, licenses and commercializes innovative and proprietary
physiological, nutritional, and behavioral treatment programs.
- - - - - -
- - - - - -
Company:
Inovio Biomedical
- - - - - -
Ticker Symbol & Exchange:
INO
- - - - - -
Investor Relations Contact:
Bernie Hertel
- - - - - -
Investor Relations Contact Phone:
858 410-3101
- - - - - -
Web:
www.inovio.com
- - - - - -
Date of Presentation:
19-May-08
- - - - - -
- - - - - -
Inovio Biomedical (AMEX: INO) is focused on developing multiple
DNA-based immunotherapies and DNA vaccines. Inovio is a leader in
developing human applications of electroporation, using brief
controlled electrical pulses to increase cellular uptake of a useful
biopharmaceutical. Human data has shown that Inovio´s
electroporation-based DNA delivery technology can significantly
increase gene expression and immune responses from DNA vaccines.
Immunotherapy partners include Merck, Wyeth, Vical, University of
Southampton, Moffitt Cancer Center, the U.S. Army, National Cancer
Institute, and International Aids Vaccine Initiative. Inovio´s
technology is protected by an extensive patent portfolio covering in
vivo electroporation.
- - - - - -
- - - - - -
Company:
Interleukin Genetics, Inc.
- - - - - -
Ticker Symbol & Exchange:
AMEX: ILI
- - - - - -
Investor Relations Contact:
Melanie Friedman
- - - - - -
Investor Relations Contact Phone:
212-362-1200
- - - - - -
Web:
http://www.ilgenetics.com
- - - - - -
Date of Presentation:
19-May-08
- - - - - -
- - - - - -
Interleukin Genetics is a science-based personalized health company
using applied genetics to empower consumers to improve their health.
Interleukin is studying the role of inflammatory genes in diseases
of aging and has commercialized the PST® Periodontal genetic test, the Gensona® IL-1 Cardiovascular genetic test and the Gensona® General Nutrition genetic test. In addition to launching its own
tests, Interleukin aims to partner with biotechnology and
pharmaceutical companies to develop molecular diagnostics.
Interleukin is also developing genetic tests to address health risks
for osteoporosis, obesity, arthritis and cancer and sells an array
of Nutraceuticals through some of the nation´s
largest retailers.
- - - - - -
- - - - - -
Company:
Lev Pharmaceuticals, Inc.
- - - - - -
Ticker Symbol & Exchange:
LEVP
- - - - - -
Investor Relations Contact:
Jason Tuthill
- - - - - -
Investor Relations Contact Phone:
212-850-9130
- - - - - -
Web:
www.levpharma.com
- - - - - -
Date of Presentation:
5/20/2008
- - - - - -
- - - - - -
Lev is a biopharmaceutical company focused on developing and
commercializing therapeutic products for the treatment of
inflammatory diseases. Lev´s lead product
candidate, Cinryzeâ„¢ (C1 inhibitor), is
being developed as a replacement therapy for both the acute and
prophylactic treatment of hereditary angioedema (HAE), also known as
C1 inhibitor deficiency. Cinryzeâ„¢ has
been granted orphan drug status for the acute and prophylactic
treatment of HAE, potentially securing, upon approval, market
exclusivity for seven years. Additionally, Lev is in the process of
prioritizing its C1 inhibitor development platform for the treatment
of selective other diseases and disorders in which inflammation is
known or believed to play an underlying role.
- - - - - -
- - - - - -
Company:
Maxygen
- - - - - -
Ticker Symbol & Exchange:
Nasdaq: MAXY
- - - - - -
Investor Relations Contact:
Michele Boudreau
- - - - - -
Investor Relations Contact Phone:
650-297-2088
- - - - - -
Web:
www.maxygen.com
- - - - - -
Date of Presentation:
19-May-08
- - - - - -
- - - - - -
Maxygen is a biopharmaceutical company focused on developing
improved versions of protein drugs. The company´s
lead program, MAXY-G34, is designed to be an improved long-acting
G-CSF for the treatment of neutropenia. MAXY-G34 is currently in
Phase II clinical trials. Also in Maxygen´s
pipeline is a new Factor VIIa product candidate for the treatment of
hemophilia and new CTLA4-Ig product candidates for the treatment of
rheumatoid arthritis. Maxygen uses its proprietary DNA shuffling
technology and extensive protein modification expertise to pursue
the creation of biosuperior proteins.
- - - - - -
- - - - - -
Company:
Neotropix, Inc.
- - - - - -
Investor Relations Contact:
Peter Lanciano, CEO; Planciano@neotropix.com
- - - - - -
Investor Relations Contact Phone:
617-460-1200
- - - - - -
Web:
www.neotropix.com
- - - - - -
Date of Presentation:
20-May-08
- - - - - -
- - - - - -
Neotropix develops several cancer drugs using a proprietary and
innovative platform sourcing natural products that selectively
bind to cancer cells and naturally kill through lysis.
- - - - - -
- - - - - -
The lead product NTX-010 is a highly selective drug that
specifically treats carcinoid, small cell and several pediatric
neuroendocrine cancers. NTX-010 is currently completing enrollment
in a large carcinoid trial. Data demonstrates the ability of
NTX-010 to obtain significant clinical effect as compared to the
control group in each of time-to-progression, reduction in tumors
and key biochemical markers. The clincal study is being conducted
at multiple USA centers including John Hopkins, USO, Mt Sinai and
Mary Crowley Cancer Research Center.
- - - - - -
- - - - - -
Company:
Novelos Therapeutics, Inc.
- - - - - -
Ticker Symbol & Exchange:
OTCBB: NVLT
- - - - - -
Investor Relations Contact:
Stephen Lichaw
- - - - - -
Investor Relations Contact Phone:
201-240-3200
- - - - - -
Web:
www.novelos.com
- - - - - -
Date of Presentation:
May 19, 2008, 2:30pm
- - - - - -
- - - - - -
Novelos Therapeutics, Inc. is a biopharmaceutical company
commercializing oxidized glutathione-based compounds for the
treatment of cancer and hepatitis. NOV-002, the lead compound
currently in Phase 3 development for lung cancer under SPA and Fast
Track, acts together with chemotherapy as a chemoprotectant and a
chemopotentiator. NOV-002 is also in Phase 2 development for
chemotherapy-resistant ovarian cancer and early-stage breast cancer.
NOV-205 acts as a hepatoprotective agent with immunomodulating and
anti-inflammatory properties. NOV-205 is in Phase 1b development for
chronic hepatitis C non-responders. Both compounds have completed
clinical trials in humans and have been approved for use in the
Russian Federation where they were originally developed.
- - - - - -
- - - - - -
Company:
Osteologix, Inc.
- - - - - -
Ticker Symbol & Exchange:
OLGX.OB
- - - - - -
Investor Relations Contact:
Baxter Phillips, III
- - - - - -
Investor Relations Contact Phone:
804.754.6970
- - - - - -
Web:
www.osteologix.com
- - - - - -
Date of Presentation:
Monday, May 19
- - - - - -
- - - - - -
Osteologix is a specialty pharmaceutical company committed to
developing innovative therapies for the treatment and prevention of
musculoskeletal diseases. It is our vision to improve the health of
those afflicted with musculoskeletal diseases such as osteoporosis.
We partner with the healthcare community to apply new scientific
information and clinical data to the development of products that
improve patient care in a safe and ethical manner. Osteologix´s
lead product candidate, NB S101, is a novel pharmaceutical agent for
the treatment and prevention of osteoporosis.
- - - - - -
- - - - - -
Company:
Pluristem Therapeutics Inc.
- - - - - -
Ticker Symbol & Exchange:
NASDAQ:PSTI; DAX:PJT
- - - - - -
Investor Relations Contact:
William Prather RPh, MD
- - - - - -
Investor Relations Contact Phone:
1-303-883-4954
- - - - - -
Web:
www.pluristem.com
- - - - - -
Date of Presentation:
20 May 2008 at 9:00 a.m.
- - - - - -
- - - - - -
Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated
to the commercialization of non-personalized (allogeneic) cell
therapy products targeting Peripheral Artery Disease (PAD), as well
as Bone Marrow Transplantation (BMT), ischemic stroke, Multiple
Sclerosis and additional autoimmune disorders, such as Crohn´s
disease. The Company´s product candidates are derived from the human
placenta, a non-controversial, non-embryonic, adult stem cell source
and are stored ready-to-use. The placental cells are expanded in the
Company´s proprietary PluriXâ„¢ 3D bioreactor and are termed PLX (PLacental eXpanded) cells.
Pluristem´s products have the potential
to participate in the approximate $30B therapeutic and regenerative
cellular market.
- - - - - -
- - - - - -
Company:
Synvista Therapeutics
- - - - - -
Ticker Symbol & Exchange:
AMEX: SYI
- - - - - -
Investor Relations Contact:
Kim Golodetz, LHA
- - - - - -
Investor Relations Contact Phone:
212-838-3777
- - - - - -
Date of Presentation:
19-May-08
- - - - - -
- - - - - -
Synvista Therapeutics is a biopharmaceutical company developing
drugs and diagnostics for cardiovascular disease and nephropathy in
diabetics. The Company´s portfolio includes orally bioavailable
organoselenium mimics of glutathione peroxidase, one of which is in
Phase 2, which metabolizes lipid peroxides and has the potential to
limit myocardial damage subsequent to myocardial infarction. It is
also developing alagebrium, a breaker of AGEs, currently in Phase 2
for treatment of heart failure. The Company is also developing
several clinical diagnostic tests, among them one for cardiovascular
risk assessment, using Haptoglobin characterization, to identify
patients at high risk for cardiovascular complications of diabetes.
- - - - - -
- - - - - -
Company:
TopoTarget A/S
- - - - - -
Ticker Symbol & Exchange:
OMX: TOPO
- - - - - -
Investor Relations Contact:
Rachel Curtis Gravesen
- - - - - -
Investor Relations Contact Phone:
45 25 12 62 60
- - - - - -
Web:
www.topotarget.com
- - - - - -
Date of Presentation:
20-May-08
- - - - - -
- - - - - -
TopoTarget is a dynamic international biotech company dedicated to
finding "Answers for cancer."
- - - - - -
- - - - - -
Founded by clinicians with a thorough knowledge of the molecular
mechanisms of cancer, our goal is to find and develop cancer
therapies, bringing them to the market to benefit patients. We have
top class experts in clinical development, regulatory and
pre-clinical departments.
- - - - - -
- - - - - -
TopoTarget´s lead product belinostat is due to begin a pivotal trial
in the second half of 2008 and we have a further 8 products in
clinical development. Using our own highly specialised dedicated
sales team, we launched our first marketed product, Savene®/Totect® in Europe/US in 2006 and 2007 respectively. Savene®/Totect® is used for the treatment of anthracycline extravasation, an
accident that can occur during chemotherapy.
- - - - - -
- - - - - -
Company:
Transdel Pharmaceuticals, Inc.
- - - - - -
Ticker Symbol & Exchange:
OTCBB: TDLP
- - - - - -
Investor Relations Contact:
John Lomoro, CFO; johnl@transdelpharma.com
- - - - - -
Investor Relations Contact Phone:
858-457-5300
- - - - - -
Web:
www.transdelpharma.com
- - - - - -
Date of Presentation:
May 19, 2008, 4:35 pm local time
- - - - - -
- - - - - -
Specialty pharmaceutical company focused on the development and
commercialization of non-invasive topically delivered medications.
The Company´s innovative patented proprietary Transdelâ„¢ cream formulation technology is designed to facilitate the effective
penetration of drugs through the tough skin barrier to reach the
target underlying tissues. In the case of Ketotransdelâ„¢
the Transdelâ„¢ cream allows the active
ingredient ketoprofen to reach the target soft tissue and exert its
well-known localized anti-inflammatory and analgesic effects. The
Company is also investigating other drug candidates and treatments
for transdermal delivery using the patented Transdelâ„¢ platform technology for products in pain management and other
therapeutic areas.
- - - - - -
Note to Editors: Business Wire´s PressPass allows you to create
free, custom Web, RSS, and email-based news feeds from more than 160
industry options, dozens of subject categories and thousands of
geographic preferences as well as by specific company filters. In
addition, PressPass subscribers have access to exclusive content
experts, company profiles, email alerts, survey services and other media
services.
Note to Event Organizers: Add your trade show, conference, or
event to http://www.tradeshownews.com
Business Wire´s online event calendar. For information, email tradeshow
(at) businesswire.com.
